BioAge Labs will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel oral NLRP3 inflammasome inhibitor. The drug targets inflammation linked to atherosclerotic cardiovascular disease and retinal diseases like diabetic macular edema. The event will feature presentations by BioAge leadership and four medical experts discussing the drug's mechanism and therapeutic potential. Phase 2 data for cardiovascular risk is expected in the second half of 2026, with retinal disease data anticipated in mid-2027.
Sun Life Global Investments declared cash distributions for June 2026 for its exchange-traded fund (ETF) series. Unitholders of record on June 23, 2026, will receive payments on June 30, 2026, with distribution amounts ranging from CAD 0.075 to CAD 0...
Parsons Corporation's stock increased following the award of design and construction oversight contracts for the John A. Blatnik Bridge replacement project, valued between $1.1 billion and $1.4 billion. The project, led by the Minnesota and Wisconsin...
Capital Link Shipping has expanded its Maritime Intelligence Hub with new executive insights from leaders at Scorpio Tankers, DHT Holdings, d’Amico International Shipping, and others. These discussions cover market trends in crude oil and product tan...
Centene, a major U.S. health insurer, has launched a voluntary separation program allowing eligible employees to apply for buyouts as it faces a significant decline in membership, especially in its Affordable Care Act (ACA) marketplace plans. Members...
Databricks has acquired cybersecurity startup Panther Labs to strengthen its position against competitors like CrowdStrike and Splunk. Panther Labs specializes in consolidating security data streams to enable automated threat responses, addressing th...
